Janux Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $10.19
- Today's High:
- $10.84
- Open Price:
- $10.72
- 52W Low:
- $10.09
- 52W High:
- $23.64
- Prev. Close:
- $10.73
- Volume:
- 60616
Company Statistics
- Market Cap.:
- $507.99 million
- Book Value:
- 7.153
- Revenue TTM:
- $7.76 million
- Operating Margin TTM:
- -995.97%
- Gross Profit TTM:
- $-44829000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -13.3%
- Return on Equity TTM:
- -21.06%
Company Profile
Janux Therapeutics Inc had its IPO on 2021-06-11 under the ticker symbol JANX.
The company operates in the Healthcare sector and Biotechnology industry. Janux Therapeutics Inc has a staff strength of 67 employees.
Stock update
Shares of Janux Therapeutics Inc opened at $10.72 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $10.19 - $10.84, and closed at $10.26.
This is a -4.38% slip from the previous day's closing price.
A total volume of 60,616 shares were traded at the close of the day’s session.
In the last one week, shares of Janux Therapeutics Inc have slipped by -6.81%.
Janux Therapeutics Inc's Key Ratios
Janux Therapeutics Inc has a market cap of $507.99 million, indicating a price to book ratio of 1.6966 and a price to sales ratio of 71.6674.
In the last 12-months Janux Therapeutics Inc’s revenue was $7.76 million with a gross profit of $-44829000 and an EBITDA of $-75741000. The EBITDA ratio measures Janux Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Janux Therapeutics Inc’s operating margin was -995.97% while its return on assets stood at -13.3% with a return of equity of -21.06%.
In Q2, Janux Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 55.3%.
Janux Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.7 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Janux Therapeutics Inc’s profitability.
Janux Therapeutics Inc stock is trading at a EV to sales ratio of 33.5613 and a EV to EBITDA ratio of -4.0253. Its price to sales ratio in the trailing 12-months stood at 71.6674.
Janux Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $341.50 million
- Total Liabilities
- $17.90 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $580000
- Dividend Payout Ratio
- 0%
Janux Therapeutics Inc ended 2024 with $341.50 million in total assets and $0 in total liabilities. Its intangible assets were valued at $341.50 million while shareholder equity stood at $299.47 million.
Janux Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $17.90 million in other current liabilities, 42000.00 in common stock, $-145437000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $33.70 million and cash and short-term investments were $303.29 million. The company’s total short-term debt was $1,408,000 while long-term debt stood at $0.
Janux Therapeutics Inc’s total current assets stands at $309.30 million while long-term investments were $0 and short-term investments were $269.59 million. Its net receivables were $0 compared to accounts payable of $1.91 million and inventory worth $0.
In 2024, Janux Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $580000.
Comparatively, Janux Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $10.26
- 52-Week High
- $23.64
- 52-Week Low
- $10.09
- Analyst Target Price
- $27.25
Janux Therapeutics Inc stock is currently trading at $10.26 per share. It touched a 52-week high of $23.64 and a 52-week low of $23.64. Analysts tracking the stock have a 12-month average target price of $27.25.
Its 50-day moving average was $11.96 and 200-day moving average was $14 The short ratio stood at 26.24 indicating a short percent outstanding of 0%.
Around 930.8% of the company’s stock are held by insiders while 9305.5% are held by institutions.
Frequently Asked Questions About Janux Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients suffering from cancer. Its lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. The company is also developing a TRACIr costimulatory bispecific product candidate against programmed death-ligand 1 and Cluster of Differentiation 28 designed to improve the anti-tumor activity of T cells. In addition, its PSMA-TRACTr is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors; EGFR-TRACTr is designed to target EGFR in various cancer types with multiple approved monoclonal antibodies; and TROP2-TRACTr is designed to target TROP2, a clinically validated anti-tumor target for which there is an approved anti-TROP2 antibody-drug conjugate. The company was incorporated in 2017 and is headquartered in San Diego, California.